Lataa...

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%–7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need f...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ther Clin Risk Manag
Päätekijät: Vallumsetla, Nishanth, Paludo, Jonas, Kapoor, Prashant
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove Medical Press 2015
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4644179/
https://ncbi.nlm.nih.gov/pubmed/26609233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S72943
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!